Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
02/24/2023* 08:00 EST Earnings Call Q4 2022 -- -- --
02/24/2023* -- Results Q4 2022 -- -0.32 --
11/03/2022 08:00 EST Earnings Call Q3 2022 -- -- --
11/03/2022 -- Results Q3 2022 -0.34 -0.42 19.05%
08/04/2022 08:00 EST Earnings Call Q2 2022 -- -- --
08/04/2022 -- Results Q2 2022 -0.46 -0.50 7.38%
05/05/2022 08:00 EST Earnings Call Q1 2022 -- -- --
05/05/2022 -- Results Q1 2022 -0.35 -0.47 24.73%
*Estimated Date/Time

Earnings

Next Report Date 02/24/2023 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 11/03/2022
Beat/Miss Upgrade
Return Since 4.28%
Last FQE 09/30/2022
Next FQE 12/30/2022

Profile

Edit
Provention Bio Inc is a clinical-stage biopharmaceutical company. It is engaged in sourcing, developing, and commercializing novel therapeutics and cutting-edge solutions to intercept and prevent immune-mediated disease, including oncological, autoimmune, and inflammatory diseases. The company's product candidates include PRV-031, for the interception, delay, or prevention of type 1 diabetes; PRV-3279, for the potential treatment of systemic lupus erythematosus; and PRV-6527, PRV-300, and PRV-101.
URL https://www.proventionbio.com
Investor Relations URL https://investors.proventionbio.com/
HQ State/Province New Jersey
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Blend
Next Earnings Release Feb. 24, 2023 (est.)
Last Earnings Release Nov. 03, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0.00%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio 0.00%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2016
2017
2018
2019
2020
2021
2022
YTD
--
--
--
741.8%
13.69%
-66.82%
88.08%
-17.03%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-18.11%
6.11%
-34.00%
-7.04%
-33.16%
-14.33%
110.1%
-29.79%
-58.19%
-14.46%
-48.76%
189.5%
-33.43%
1.67%
137.1%
-49.98%
5.71%
5.08%
-41.45%
103.4%
10.58%
32.13%
7.94%
-7.08%
31.50%
11.31%
-93.85%
-35.40%
-61.54%
615.0%
-19.46%
142.0%
28.05%
5.79%
As of January 27, 2023.

Profile

Edit
Provention Bio Inc is a clinical-stage biopharmaceutical company. It is engaged in sourcing, developing, and commercializing novel therapeutics and cutting-edge solutions to intercept and prevent immune-mediated disease, including oncological, autoimmune, and inflammatory diseases. The company's product candidates include PRV-031, for the interception, delay, or prevention of type 1 diabetes; PRV-3279, for the potential treatment of systemic lupus erythematosus; and PRV-6527, PRV-300, and PRV-101.
URL https://www.proventionbio.com
Investor Relations URL https://investors.proventionbio.com/
HQ State/Province New Jersey
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Blend
Next Earnings Release Feb. 24, 2023 (est.)
Last Earnings Release Nov. 03, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

No data available
Symbol Dollars Invested % Weight
     
     
     
     
     
     
     
     
     
     

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Nasdaq Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter PRVB Tweets